血红蛋白病的临床试验
总计1337个结果
-
Augusta UniversityNational Heart, Lung, and Blood Institute (NHLBI); Gilead Sciences完全的
-
National Heart, Lung, and Blood Institute (NHLBI)完全的
-
London North West Healthcare NHS TrustMedical Research Council CTU终止
-
Assistance Publique - Hôpitaux de Paris尚未招聘
-
The 923rd Hospital of Joint Logistics Support Force...Guangzhou Reforgene Medicine Co., Ltd.招聘中
-
Brown UniversityNational Heart, Lung, and Blood Institute (NHLBI); Novartis招聘中
-
Phoenicia BioScienceNational Heart, Lung, and Blood Institute (NHLBI)招聘中
-
Hospices Civils de Lyon完全的
-
National Heart, Lung, and Blood Institute (NHLBI)完全的
-
Queen Fabiola Children's University Hospital未知
-
Reprixys Pharmaceutical CorporationNational Heart, Lung, and Blood Institute (NHLBI); Food and Drug Administration (FDA)完全的
-
HaEmek Medical Center, Israel未知
-
University of Texas Southwestern Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)完全的
-
Faculdade Adventista da BahiaFederal University of Bahia未知
-
University of RochesterBayer; University of Miami; National Institute of Neurological Disorders and Stroke (NINDS)完全的镰状细胞性贫血症
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH); University... 和其他合作者完全的
-
Vertex Pharmaceuticals IncorporatedCRISPR Therapeutics邀请报名血液病 | 先天性遗传病 | 镰状细胞性贫血症 | 血红蛋白病 | 镰状细胞性贫血 | 地中海贫血 | Β-地中海贫血美国, 加拿大, 意大利, 英国, 德国
-
Hospital de Clinicas de Porto AlegreFundo de Incentivo à Pesquisa do Hospital de Clinicas de Porto Alegre (FIPE); Associação de... 和其他合作者完全的
-
Editas Medicine, Inc.尚未招聘镰状细胞性贫血症 | 血红蛋白病 | 输血依赖性β-地中海贫血
-
Institute of Hematology & Blood Diseases Hospital招聘中
-
Bristol-Myers Squibb招聘中
-
Vertex Pharmaceuticals IncorporatedCRISPR Therapeutics招聘中血液病 | 先天性遗传病 | 镰状细胞性贫血症 | 血红蛋白病 | 镰状细胞性贫血 | 地中海贫血 | Β-地中海贫血美国, 意大利, 德国, 沙特阿拉伯
-
Vanderbilt University Medical CenterAminu Kano Teaching Hospital; Murtala Muhammad Specialist Hospital完全的
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Helen Keller International; DSM Nutritional Products... 和其他合作者完全的
-
Novartis Pharmaceuticals撤销Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD